Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EMA Head On Transparency, Affordable Innovation, And What Patients Really Need

Executive Summary

EMA will reinforce its role as a global reference authority and help build regulatory capacity in less experienced countries, Guido Rasi says in outlining his five-year priorities for the agency. He hopes regulatory efficiencies might contribute to lower drug prices.

You may also be interested in...



European Notebook: EMA’s 2016 Work Agenda; Clinical Trial Rule Delay; Ireland Benefits From Pfizer Merger

The European Medicines Agency wants to accelerate clinical development plans with new processes and procedures in 2016 and companies must disclose payments to providers starting mid-year; Ireland and Switzerland look set to grapple with high drug prices, and France's industry wants to reverse the erosion of jobs.

European Notebook: EMA’s 2016 Work Agenda; Clinical Trial Rule Delay; Ireland Benefits From Pfizer Merger

The European Medicines Agency wants to accelerate clinical development plans with new processes and procedures in 2016 and companies must disclose payments to providers starting mid-year; Ireland and Switzerland look set to grapple with high drug prices, and France's industry wants to reverse the erosion of jobs.

Adaptive Licensing: Industry On Board, With Caveats

The EU's adaptive licensing pilot project, which was launched in March 2014, is designed to deliver an early centralized marketing license for promising innovative therapies for patients with serious or life-threatening conditions. However, while the benefits are clear, there are a number of challenges that will need to be addressed.

UsernamePublicRestriction

Register

OM013214

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel